x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

The Readout Loud

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

business

All Episodes

58:47

337: Eli Lilly CEO on Trump, obesity drugs, and a...

The Readout Loud ·

2025/01/15

We're live at the J.P Morgan Healthcare Conference in San Francisco! We bring on Eli Lilly CEO Dave Ricks for a wide-ranging conversation about his views on the incoming Trump administration, the effects of Medicare's drug price negotiation, Lilly's recent disappointing guidance, pricing of the company's obesity medication Zepbound, and more. We also discuss the latest news from the J.P. Morgan conference, including M&A deals, licensing of drugs from China, and the broader sentiment in the

en

33:21

336: Pharma's big patent cliff, more obesity...

The Readout Loud ·

2025/01/09

We chat about how pharmaceutical companies are navigating a looming patent cliff. We also talk about yet another obesity startup and a failed study from Google’s secretive anti-aging company Calico.

en

33:43

335: A deep dive on Makary, Vertex's pain data, &...

The Readout Loud ·

2024/12/19

STAT's FDA reporter Lizzy Lawrence joins us to discuss her profile of Marty Makary, Trump's nominee for FDA commissioner. Then, we discuss the results of Vertex's latest pain drug trial, the medication launches to watch in 2025, and present our burning questions for the biopharma industry.

en

34:30

334: Pharma silence on RFK Jr. & parents trying to...

The Readout Loud ·

2024/12/12

Washington correspondent John Wilkerson joins to discuss why drugmakers have not lobbied against Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services, despite his repeated criticisms of the pharmaceutical industry. We also bring on our colleague Jason Mast to talk about the major hurdles in the field of gene therapy and how one father is trying to overcome them.

en

27:55

333: An H5N1 bird flu update and talent scarcity in...

The Readout Loud ·

2024/12/05

You might not be paying attention, or maybe you just hope it goes away. We’re referring to the serious bird flu outbreak that started a bit more than eight months ago. Well, bird flu is still here and the number of reported cases in people is growing. STAT’s infectious disease reporter Helen Branswell joins us for an update. But first, we break down the results from a GLP-1 showdown study that compared Eli Lilly’s Zepbound to Novo Nordisk’s Wegovy. Allison shares her recent reporting on a talent

en

35:08

332: Pfizer's new R&D head, a VC deep-dive, and a new...

The Readout Loud ·

2024/11/21

Atlas Venture Partner Bruce Booth joins the podcast to discuss his annual year in review report, the influence of China, and what the new Trump administration might mean for innovation. Adam and Allison also recap the latest news in the life sciences, including a new science chief at Pfizer, a new job for Ned Sharpless, and the ongoing presidential appointments.

en

30:16

331: AbbVie’s stumble, Amgen’s tumble and more...

The Readout Loud ·

2024/11/14

Why are AbbVie executives feeling the M&A blues? What does it take to slice $12 billion from Amgen’s market value? And why are STAT’s D.C. correspondents working so hard? We talk about all that and more on this week’s episode of the “The Readout LOUD,” STAT’s biotech podcast. It’s a “Chatty Cathy” episode! Elaine, Allison and Adam lead off with a discussion about AbbVie’s M&A miscue following the failure of a closely followed schizophrenia drug. You’d hate us if obesity drugs weren’t mentioned, so

en

39:22

330: How a Trump presidency could affect the FDA, the...

The Readout Loud ·

2024/11/07

To dig into how the election results could affect all things biopharma, we brought on three guests for this episode: Lizzy Lawrence, STAT’s FDA reporter, Baird analyst Brian Skorney, and longtime biotech executive Daphne Zohar.

en

28:25

329: Lilly's earnings surprise, investors mull the...

The Readout Loud ·

2024/10/31

Adam, Allison, and Elaine get into the Halloween spirit this week, discussing their favorite candies — and Eli Lilly and Pfizer's surprise earnings reports. Then, they discuss what a Trump or Harris presidency could mean for health care and the biopharma industry, and what investors and biopharma executives think about either outcome.

en

33:46

328: Pfizer's activist troubles, gene therapy...

The Readout Loud ·

2024/10/24

Will an activist investor campaign against Pfizer lead to big changes at the struggling Pharma giant? Why are some experts questioning the regulatory standards used to approve gene therapies for Duchenne muscular dystrophy? What’s the difference between Novo Holdings and Novo Nordisk, and will it impact a $16 billion acquisition of Catalent? And what lies ahead for Robert F. Kennedy Jr. and the Make America Healthy Again movement?

en

34:19

327: Biotech's next gold rush, GLP-1 shortages, and...

The Readout Loud ·

2024/10/17

Elaine, Allison, and Adam chat about investors' interest in using CAR-T to treat autoimmune conditions, the latest developments with the supply of Eli Lilly’s blockbuster weight loss drug, and the invisible medical groups behind the dozens of telehealth platforms providing GLP-1 drugs. They also look back at STAT's two-day summit that brought together biopharma executives, scientists, policymakers and patient advocates for conversations about the future of health care.

en

40:08

326: Crypto for CRISPR, a new RNAi startup, & a Nobel...

The Readout Loud ·

2024/10/10

First, biotech veteran John Maraganore calls in to discuss his new startup, City Therapeutics, this week's Nobel Prize awards, and the nerdy accolade he just received. Then STAT's Megan Molteni tells us about "CRISPR baby" scientist He Jiankui and his new cryptocurrency financier.

en

32:48

325: Biden's health care AI czar, a new obesity...

The Readout Loud ·

2024/10/03

Our colleague Mohana Ravindranath joins us to talk about Micky Tripathi, charged with coordinating how AI is used across different government agencies and more broadly across the health care industry. We also chat about some important biotech study readouts due before the end of the year, a new, well-funded obesity company, and the successful serial CEO running it. Finally, Adam and Allison lament the fact that Elaine hasn't yet watched the first episode of this season's "Great British Baking

en

28:08

From Tradeoffs: Race to the Bottom

The Readout Loud ·

2024/09/28

We’re excited to share the first episode in a new podcast series on generic drugs from Tradeoffs. It’s called ‘Race to the Bottom,’ and each week the show examines the problems undermining the generic drugs we all rely on — and how we could fix them. Take a listen, and we’ll see you next week.

en

32:02

324: Genentech's cancer pivot, Pfizer's sickle cell...

The Readout Loud ·

2024/09/26

Our colleague Jonathan Wosen joins us to discuss the recent setbacks and wins in oncology R&D, including Genentech's decision to shut down its cancer immunology group, and the global ambitions of Akeso, the Chinese biotech behind Summit Therapeutics’ recent positive results. We also chat about the latest news in the life sciences, including Pfizer’s sudden announcement to pull its sickle cell drug and the imminent approval of Bristol Myers Squibb’s schizophrenia treatment.

en

35:21

323: Cannabinoids for weight loss, a cancelled ad...

The Readout Loud ·

2024/09/19

Mizuho analyst Jared Holz joins us to discuss what the Federal Reserve's long-awaited decision to lower interest rates means for biotech stocks and startups. Elaine, Adam, and Allison also discuss the latest news in life sciences, including the use of cannabinoid receptor drugs in weight loss and the Lasker Awards, a.k.a. "America's Nobel."

en

32:57

322: A new threat to Merck's blockbuster cancer...

The Readout Loud ·

2024/09/12

STAT reporter Matt Herper joins us to break down all the angles of this week's tumultuous week in cancer immunotherapy, including his up-close look at Summit co-CEO Bob Duggan. We also discuss the latest news in the life sciences, including Moderna pruning its pipeline and its spending, plus results from a study that tested a GLP-1 drug in children.

en

35:18

321: Summit's upcoming cancer results, Recursion's...

The Readout Loud ·

2024/09/05

We discuss the next big trend in obesity drug development — treatments that target the amylin hormone. Companies argue that these types of drugs could lead to less nausea and muscle loss, and the first big readout is coming later this year. We also chat about an upcoming presentation from Summit Therapeutics on its cancer drug that beat Merck’s Keytruda, mixed data from Recursion’s lead AI-derived drug candidate, and more news in the life sciences.

en

37:34

320: Jim Wilson's next venture, a surprise startup...

The Readout Loud ·

2024/08/29

STAT biotech reporter Jonathan Wosen joins us to discuss gene therapy pioneer Jim Wilson's exit from his decades-long tenure at the University of Pennsylvania. We also discuss the latest news in the life sciences, including the surprising collapse of a gene editing company, Eli Lilly's pitch to consumers, and more.

en

22:42

From "Say More": What Happens When AI Decides Your...

The Readout Loud ·

2024/08/23

This week, STAT's Casey Ross and Bob Herman joined the Boston Globe's "Say More" podcast to talk about their reporting on AI and Healthcare. We're sharing that episode here with you now. Enjoy!

en

381 results

Similar Podcasts

TaxTalent.com The Golden Rule Podcast

Adam Golden

TaxTalent.com Podcast

Tony Santiago

Handelsblatt Crime - spannende Streitfälle der deutschen Wirtschaft

Ina Karabasz, Solveig Gode, Sönke Iwersen

Deffner und Zschäpitz – Der Wirtschafts-Talk von WELT

WELT

Black Box - La scatola nera della finanza

Guido Brera e Gian Luca Comandini -...